ArticleTherapeutic advances in hematology2026
Prognostic value of early lymphocyte dynamics during blinatumomab therapy in relapsed or refractory B-cell precursor acute lymphoblastic leukemia: A real-world retrospective study.
Article in Therapeutic advances in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Blinatumomab, a bispecific T-cell engager, mediates cytotoxicity through CD3+ T-cell activation and has shown efficacy in relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Although T-cell expansion correlates with favorable outcomes, routine immunophenotyping is impractical in clinical settings. Objectives: To determine whether early changes in absolute lymphocyte count (ALC), a readily available laboratory marker, can serve as a surrogate indicator of therapeutic response and long-term survival in patients receiving blinatumomab. Design: A retrospective cohort study of adult patients with R/R BCP-ALL treated with blinatumomab. Methods: We analyzed 162 adults with R/R BCP-ALL who received up to two cycles of blinatumomab. The primary outcome was complete remission (CR), and secondary outcomes included overall survival (OS). ALC change from day 1 to day 14 (ΔALC14) was calculated, and its association with outcomes was assessed using logistic and Cox regression models. Results: Of the 162 patients, 106 (65.4%) achieved CR. ΔALC14 was significantly greater in responders than in non-responders (median 0.344 vs. 0.146 × 10 Conclusion: Early lymphocyte expansion during blinatumomab therapy, reflected by ΔALC14, is an independent predictor of treatment response. ALC monitoring may offer a simple, cost-effective tool for risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.